Sulpiride
 | |
|---|---|
| Systematic (IUPAC) name | |
| (±)-5-(aminosulfonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide | |
| Identifiers | |
| CAS number | 15676-16-1 |
| ATC code | N05AL01 N05AL07 |
| PubChem | CID 5355 |
| DrugBank | APRD00032 |
| ChemSpider | 5162 |
| UNII | 7MNE9M8287 |
| KEGG | D01226 |
| ChEMBL | CHEMBL26 |
| Chemical data | |
| Formula | C15H23N3O4S |
| Mol. mass | 341.427 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | 25–35% |
| Half-life | 7 hours |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | ℞ Prescription only |
| Routes | Oral |
 (what is this?) (verify) | |
Sulpiride (sold as Meresa, Bosnyl, Dogmatil, Eglonyl, Modal) is a atypical antipsychotic drug of the benzamide class used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder. Sulpiride is more commonly used in Europe and Japan. Levosulpiride is its purified levo- isomer and is sold in India for similar purpose. So far it has not been approved in the United States and Canada. The drug has strong chemical and clinical similarities to the related antipsychotic amisulpride.
Uses and dosage
Pharmacology
Pharmacokinetics
Sulpiride is absorbed slowly from the gastrointestinal tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences. The peak plasma concentration is reached 4.5 hours after oral dosing. The usual half-life is 6 to 8 hours. Ninety-two percent is excreted unchanged in the urine. Sulpiride is usually given in 2 or 3 divided doses.
Pharmacodynamics
Sulpiride is a selective antagonist at dopamine D2 and D3 receptors. This action dominates in doses exceeding 600 mg daily. In doses of 600 to 1,600 mg sulpiride shows mild sedating and antipsychotic activity. Its antipsychotic potency compared to chlorpromazine is only 0.2 (1/5). In low doses (in particular 50 to 200 mg daily) its prominent feature is antagonism of presynaptic inhibitory dopamine receptors accounting for some antidepressant activity and a stimulating effect. Therefore, it is in these doses used as a second line antidepressant. Additionally, it alleviates vertigo.
The benzamide neuroleptics (including sulpiride, amisulpride, and sultopride) have been shown to activate the endogenous gamma-hydroxybutyrate receptor in vivo at therapeutic concentrations. Sulpiride was found in one study in rats to upregulate GHB receptors. GHB has neuroleptic properties and it is believed binding to this receptor may contribute to the effects of these neuroleptics.
Side effects
Sulpiride has fewer extrapyramidal side effects (dystonia, parkinsonism, tardive dyskinesia, and akathisia) than many of the older antipsychotic medications. Most of these do not seem to occur in a dose related manner. Other side effects occur infrequently (hypotension, rarely long-QT syndrome, dry mouth, sweating, nausea, activation or sedation, insomnia, allergic rash or pruritus). Isolated cases of the potentially life-threatening NMS (neuroleptic malignant syndrome) have been reported. Sulpiride should not be taken after 4 p.m. in order to avoid insomnia. The foremost problem with sulpiride is a strong stimulation of prolactin-secretion; whether this may contribute to the development of breast-cancer in women is currently not known.
Overdose
Sulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trismus. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur. The treatment is largely symptomatic. Some or all extrapyramidal reactions may respond to the application of anticholinergic drugs such as biperiden or benztropine. All patients should be closely monitored for signs of long-QT syndrome and severe arrhythmias.
Contraindications and cautions
Pregnancy and lactation
Chemistry
Sulpiride, (N-[(1-ethyl-2-pirrolidinylmethyl]-5-sulfamoyl-O-anizamide) is synthesized from 5-aminosulfosalicylic acid. Methylating this with dimethylsulfate gives 2-methoxy-5-aminosulfonylbenzoic acid, which is transformed into an amide using 2-aminomethyl-1-ethylpyrrolidine as the amine component and carbonyldiimidazole (CDI) as a condensing agent.
See also
References
Retrieved from : http://en.wikipedia.org/wiki/Sulpiride
